Epigral Ltd
EPIGRALEpigral Ltd
EPIGRAL
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 28.61 | 6.42 | 0.25% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 29.46 | 3.34 | 1.38% |
Forecast & Ratings
Detailed Forecast from 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Epigral Limited (formerly Meghmani Finechem Limited) is a manufacturer of essential chemicals, primarily focused on the production of chlor alkali and its derivatives, used across various industries.
Peers
Compare with peersSolar Industries India Ltd
Linde India Ltd
Deepak Nitrite Ltd
Sumitomo Chemical India Ltd
Himadri Speciality Chemical Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 830.79 | 1,555.05 | 2,196.38 | 1,935.78 | 2,286.72 | |||||
Raw Materials | 386.52 | 759.41 | 1,211.76 | 1,071.60 | 1,640.79 | |||||
| Power & Fuel Cost | 27.93 | 64.15 | 145.56 | 141.32 | ||||||
| Employee Cost | 41.26 | 51.99 | 68.85 | 81.31 | ||||||
| Selling & Administrative Expenses | 21.35 | 47.85 | 57.01 | 54.12 | ||||||
| Operating & Other expenses | 90.22 | 118.06 | 16.30 | 99.64 | ||||||
EBITDA | 263.51 | 513.59 | 696.90 | 487.79 | 645.93 | |||||
| Depreciation/Amortization | 73.54 | 85.91 | 108.95 | 123.56 | 126.96 | |||||
| PBIT | 189.97 | 427.68 | 587.95 | 364.23 | 518.97 | |||||
| Interest & Other Items | 29.11 | 44.27 | 65.50 | 73.49 | 75.45 | |||||
| PBT | 160.86 | 383.41 | 522.45 | 290.74 | 443.52 | |||||
| Taxes & Other Items | 60.02 | 130.63 | 169.17 | 94.88 | 150.00 | |||||
| Net Income | 100.84 | 252.78 | 353.28 | 195.86 | 293.52 | |||||
| EPS | 24.27 | 60.84 | 85.02 | 47.14 | 70.64 | |||||
| DPS | 0.00 | 0.00 | 5.00 | 5.00 | 5.00 | |||||
| Payout ratio | 0.00 | 0.00 | 0.06 | 0.11 | 0.07 |
Company Updates
Annual report
PDFPeers & Comparison
MaterialsCommodity Chemicals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Epigral Ltd | 42.88 | 6.42 | 0.25% |
| Solar Industries India Ltd | 108.65 | 26.50 | 0.08% |
| Linde India Ltd | 127.80 | 15.99 | 0.18% |
| Deepak Nitrite Ltd | 44.92 | 7.55 | 0.28% |
Price Comparison
Compare EPIGRAL with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Mar 2024
Jun 2024
Sep 2024
Oct 2024
Shareholding History
Mutual Funds Holding Trend
No mutual funds holding trends are available
Top 5 Mutual Funds holding Epigral Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
HSBC Focused Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5312% | Percentage of the fund’s portfolio invested in the stock 2.54% | Change in the portfolio weight of the stock over the last 3 months 2.54% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/37 (+12) |
HSBC Value Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5105% | Percentage of the fund’s portfolio invested in the stock 0.32% | Change in the portfolio weight of the stock over the last 3 months 0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 73/78 (+3) |
HSBC Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5054% | Percentage of the fund’s portfolio invested in the stock 1.00% | Change in the portfolio weight of the stock over the last 3 months 1.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 77/107 (+25) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 2, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Jul 2, 2024
Cash Dividend
Ex DateEx DateJun 20, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Jun 20, 2023
Cash Dividend
Ex DateEx DateFeb 1, 2023
Dividend/Share
₹2.50
Ex DateEx Date
Feb 1, 2023
Net profit of Epigral rose 114.00% to Rs 81.30 crore in the quarter ended September 2024 as against Rs 37.99 crore during the previous quarter ended September 2023. Sales rose 30.93% to Rs 626.06 crore in the quarter ended September 2024 as against Rs 478.15 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales626.06478.15 31 OPM %28.5022.53 - PBDT157.4387.45 80 PBT125.1855.94 124 NP81.3037.99 114 Powered by Capital Market - Live
The Board of Epigral at its meeting held on 09 November 2024 has approved the expansion of production capacity of Chlorinated Polyvinyl Chloride Resin (CPVC Resin) and Epichlorohydrin at Dahej, Gujarat at an estimated capex of Rs 780 crore. Details: CPVC Resin - Proposed capacity addition 75,000 TPA (existing capacity 75,000 TPA; 65% capacity utilization) Epichlorohydrin - Proposed capacity addition 50,000 TPA (existing capacity 50,000 TPA; 80% capacity utilization) Powered by Capital Market - Live
Epigral will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live
Epigral has allotted 15,19,180 equity shares at an issue price of Rs 2093.13 per equity share under QIP issue for a consideration of Rs 333.05 crore. With this allotment, the paid up equity share capital has increased to Rs 43,14,13,380 consisting of 4,31,41,338 equity shares. Powered by Capital Market - Live
The Board of Epigral at its meeting held on 14 August 2024 has approved fund raising up to Rs 500 crore through issue of securities on preferential allotment basis or qualified institutional placement. Powered by Capital Market - Live
Epigral will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
The Board of Epigral will meet on 14 August 2024 to consider proposal for raising of funds through various options. Powered by Capital Market - Live
Revenue from operations jumped 43% to Rs 651.20 crore in Q1 FY25 from Rs 454.89 crore posted in Q1 FY24. Profit before tax (PBT) soared to Rs 130.96 crore in Q1 FY25 as compared with Rs 47.41 crore in Q1 FY24. EBITDA stood at Rs 176 crore as against Rs 95 crore in Q1FY24, resgitering the growth of 85% YoY. EBIDTA margin stood at 27% in Q1FY25 as compared with 21% in Q1FY24 on account of increase in utilization and volume contribution from new projects commissioned. Volume grew 29% YoY and 14% QoQ. Major growth comes from Derivatives this growth is primarily attributed to efficient utilization of capacities and also volume from new projects commissioned. Revenue contribution from Derivatives & Specialty business rose sharply and stood at 53% in Q1FY25 vs 37% in Q1FY24. In the April to June 2024 quarter, we commissioned CPVC Resin and Compound facility and by the end of current quarter we expect to commission Chlorotoluenes Value Chain facility, both these projects will drive growth for Epigral in FY2025 and FY2026. We are moving in line with our long term vision to become fully integrated complex catering to diversified industries and grow consistently to create value for our stakeholders.' Epigral, formerly known as Meghmani Finechem, is a leading integrated manufacturer of chemicals in India. The company is the first to set up an Epichlorohydrin plant in the country and is also the largest capacity plant of CPVC Resin. Epigral is also India's fourth largest manufacturer of caustic soda, chlorine and hydrogen and a leading manufacturer of caustic potash, chloromethanes and hydrogen peroxide. The scrip hit a 52 week high at Rs 1,720 in today's intra-day session. Powered by Capital Market - Live
Net profit of Epigral rose 172.52% to Rs 85.87 crore in the quarter ended June 2024 as against Rs 31.51 crore during the previous quarter ended June 2023. Sales rose 43.16% to Rs 651.20 crore in the quarter ended June 2024 as against Rs 454.89 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales651.20454.89 43 OPM %27.0720.89 - PBDT164.4178.21 110 PBT130.9647.41 176 NP85.8731.51 173 Powered by Capital Market - Live
Epigral will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant